UniQure sells part of Hemgenix royalty for $400M cash
UniQure sold part of its lucrative Hemgenix royalty rights to a pair of investment firms for up to $400 million in cash.
The Dutch biotech said Monday that part of its royalty rights are being sold to HealthCare Royalty (HCRx) and Sagard Healthcare going into the next decade. The gene therapy was approved last year as a treatment for hemophilia B at a list price of $3.5 million.
The buyers will pay uniQure an upfront payment of $375 million. An additional $25 million is on the line, if sales of the gene therapy reach an undisclosed amount in 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.